Vaxart Stock is up over 165% after after the biotechnology company announced results from a phase 2 trial that its oral flu vaccine performed better than Sanofi's Fluzone.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,